Watch Ticker

Jazz Pharmaceuticals, Inc.

Go to Jazz Pharmaceuticals, Inc. Website

$116.20

0.68 (0.59%)

Live

Previous Close

$115.52

Day Range

$114.715 - $117.39

Previous Day Range

$112.17 - $115.76

Market Cap

$7.0 billion USD

Day Vol.

597906

Previous Day Vol.

598969

Currency

USD

Primary Exchange

Nasdaq

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Zymeworks Inc. - Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 7, 2025, and participate in upcoming investor conferences. The company has received regulatory approvals for zanidatamab, a HER2-targeted bispecific antibody for biliary tract cancer treatment.

Related tickers: ZYME, ONC, JAZZ.

Read Full Article

Avadel Pharmaceuticals - Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Avadel Pharmaceuticals won a unanimous Appeals Court decision upholding the FDA's approval of LUMRYZ, a once-at-bedtime narcolepsy treatment, in litigation brought by Jazz Pharmaceuticals.

Related tickers: AVDL, JAZZ.

Read Full Article

Trending Tickers

Please sign in to view